DrugBiological
Bempegaldesleukin clinical trials
Also written NKTR-214 and BMS-986321.
- studies test it
- 18
- open now
- 1
- in phase 3
- 5
- first study started
- 2015
Keep track of what changes. Save the bempegaldesleukin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 9
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 4
Nektar Therapeutics (8) · Bristol-Myers Squibb (4) · Memorial Sloan Kettering Cancer Center (1) · Parker Institute for Cancer Immunotherapy (1) · Nykode Therapeutics ASA (1) · The First Affiliated Hospital with Nanjing Medical University (1) · University of Wisconsin, Madison (1) · Calithera Biosciences, Inc (1)
Often tested with
Tested in the same studies.
Nivolumab (8) · CDX-301 (1) · flt3 ligand protein (1) · Poly ICLC (1) · DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Formulation INO-5151 (1) · Anlotinib (1) · Pembrolizumab (1) · Resiquimod pegol (1)
Studies
Open first, then newest update. How each study uses bempegaldesleukin is read from its arms, and is right about nine times in ten.
Testing it · 18
- A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.Not yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07156643Written as Anlotinib and bempegaldesleukin
- A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03282344Written as NKTR-214
- A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaCompletedPhase 3Bristol-Myers SquibbNCT03635983Written as NKTR-214
- A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerCompletedPhase 3Bristol-Myers SquibbNCT04209114Written as Bempegaldesleukin
- Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsCompletedPhase 1Parker Institute for Cancer ImmunotherapyNCT03835533Written as NKTR-214 (Cohort A)
- Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell CarcinomaTerminatedPhase 2University of Wisconsin, MadisonNCT04936841Written as NKTR-214
- A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19CompletedPhase 1Nektar TherapeuticsNCT04646044Written as Bempegaldesleukin
- A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic CancerCompletedPhase 1/2Nykode Therapeutics ASANCT03548467Written as Bempegaldesleukin
- Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrenceTerminatedPhase 3Nektar TherapeuticsNCT04410445Written as Bempegaldesleukin
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)TerminatedPhase 3Nektar TherapeuticsNCT03729245Written as bempegaldesleukin
- A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial CancerCompletedPhase 2Nektar TherapeuticsNCT03785925Written as Bempegaldesleukin
- A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerTerminatedPhase 1/2Bristol-Myers SquibbNCT04730349Written as NKTR-214
- REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesTerminatedPhase 1/2Nektar TherapeuticsNCT03435640Written as bempegaldesleukin
- A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)WithdrawnPhase 1Calithera Biosciences, IncNCT03772288Written as NKTR-214
- BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)TerminatedPhase 2/3Nektar TherapeuticsNCT04969861Written as Bempegaldesleukin
- An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT03745807Written as NKTR-214
- A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid TumorsCompletedPhase 1/2Nektar TherapeuticsNCT02869295Written as NKTR-214
- A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and NivolumabWithdrawnPhase 1Nektar TherapeuticsNCT04955262Written as Bempegaldesleukin (NKTR-214)
Given in every arm · 2 — bempegaldesleukin is usual care beside what is tested
- Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid TumorsTerminatedPhase 1/2Nektar TherapeuticsNCT03138889Written as NKTR-214
- Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid TumorsTerminatedPhase 1/2PfizerNCT04052204Written as Bempegaldesleukin
Codes
What other systems call bempegaldesleukin · ClinicalTrials.gg INT000548
- MeSH (NLM) C000611752bempegaldesleukinOne source NLM
- UNII (FDA) BNO1JG5MZCBEMPEGALDESLEUKINConfirmed FDA, NLM, Wikidata
- Wikidata Q68010523bempegaldesleukinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C131019BempegaldesleukinOne source FDA
- DrugBank DB15140One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000611752 | bempegaldesleukin | One source NLM |
| UNII (FDA) | BNO1JG5MZC | BEMPEGALDESLEUKIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q68010523 | bempegaldesleukin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C131019 | Bempegaldesleukin | One source FDA |
| DrugBank | DB15140 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.